PlexBio Co., Ltd. develops and manufactures in vitro diagnostic reagents for molecular biology and immunology projects. It offers workflow navigation services; automated sample preparation extraction kits; IntelliPlex platform that is designed for pCode technology with for sample-to-answer multiplexing assays; oncology kits for lung cancer and mutation detection, as well as rearrangements; IntelliPlex SARS-CoV-2 detection test kits/flu kits and IntelliPlex SARS-CoV-2 variant analysis kits; and pCode coupling buffer sets. PlexBio Co., Ltd. was founded in 2009 and is based in Taipei, Taiwan.
Metrics to compare | 6572 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship6572PeersSector | |
---|---|---|---|---|
P/E Ratio | −16.9x | 0.0x | −0.5x | |
PEG Ratio | 3.19 | 0.00 | 0.00 | |
Price/Book | 2.8x | 0.0x | 2.6x | |
Price / LTM Sales | 8.1x | 0.0x | 3.3x | |
Upside (Analyst Target) | - | 0.0% | 40.1% | |
Fair Value Upside | Unlock | 0.0% | 5.1% | Unlock |